NanoViricides to Lead Sessions at the Symposium on Nanomedicines- Roadmap to Commercialization, in Rockville, MD tomorrow

WEST HAVEN, Conn.–(BUSINESS WIRE)– NanoViricides, Inc. (OTC BB: NNVC) (the “Company”) announced today that its President, Dr. Anil Diwan, will lead the Section 1, “Designing Nanomedicines“, with Dr. Mostafa Analoui of the Livingston Group. In addition, Dr. Randall Barton, the Company’s Chief Scientific Officer, will lead Section 2, “Preclinical Pharmacology”, with Dr. Benjamin Yerxa of Liquidia Technologies. These sections are part of the Symposium on Nanomedicines: Charting a Roadmap to Commercialization, which is divided into five sections. The Symposium is being held at the Hilton Hotel in Rockville, MD, on the 6th and 7th of March. Section 1 is scheduled for tomorrow, March 6th, at 10:0 am, and Section 2 follows the same day at 11:30am.

The section 1 on “Designing Nanomedicines” is organized to provide a sampling of the multi-faceted nanomedicine technologies and their current and future applications. Panel presenters include: Professor Philip S. Low, Purdue University, Professor Edith Mathiowitz, Brown University, Professor Justin Hanes, Johns Hopkins University, Dr. Uma Prabhakar, Office of Cancer Nanotechnology Research at NCI-NIH, and Dr. Frank Bedu-Addo, PDS Biotechnologies, in addition to Dr. Diwan and Dr. Analoui. The panelists will briefly present design aspects of their respective work in nanomedicines and then discuss several key questions that should be addressed in developing novel nanomedicines against diseases that currently have no good drugs.

Dr. Diwan will focus on the questions of how to design antiviral biomimetic nanomedicines, as exemplified by nanoviricides®, how important is the direct, zip-code-like “active” targeting for such drugs, the Company’s success in developing the first ever orally active nanomedicine (oral FluCide™ anti-influenza drug candidate), success in achieving “broad-spectrum” effectiveness, successful design of ocular delivery, and success in achieving long, sustained, in-vivo effectiveness, as exemplified by the Company’s anti-HIV as well as anti-Influenza drug candidates. The sustained effect may enable single dose therapy for influenza and other acute viral illnesses. In addition, this sustained effect property should result in strong patient benefits for HIV/AIDS patients by reducing the number of times the drug needs to be taken, to perhaps as little as once-a-week.

A single course treatment for out-patients is a highly sought after goal in influenza therapeutics. In addition, broad-spectrum effectiveness against most, if not all, influenza viruses is very important because the influenza A virus changes rapidly every season. During the 2009 H1N1 “swine flu” pandemic, approximately 61 million cases of out-patient influenza were estimated in the USA alone.

The Company’s anti-influenza clinical drug candidate is expected to be …read more
Source: FULL ARTICLE at DailyFinance